20(S)-Ginsenoside Rh2 Noncompetitively Inhibits P-Glycoprotein In Vitro and In Vivo: A Case for Herb-Drug Interactions
Authors:
- Fang ZhouFZFang Zhou
- Xiaolan WuXWXiaolan Wu
- Yi GuYGYi Gu
- Hua AiHAHua Ai
- Yuanting ZhengYZYuanting Zheng
- Yannan LiYLYannan Li
- Xiaoxuan ZhangXZXiaoxuan Zhang
- Gang HaoGHGang Hao
- Jianguo SunJSJianguo Sun
- Ying PengYPYing Peng
- Guangji WangGWGuangji Wang
- 1 December 2010
- journal article
- Published by Elsevier in Drug Metabolism and Disposition
- Vol. 38 (12) , 2179-2187
Abstract
P-glycoprotein (P-gp) is an ATP-dependent efflux transporter highly expressed in gastrointestinal tract and multidrug resistance tumor cells. Inhibition or induction of P-gp can cause drug-drug interactions and thus influence the effects of P-gp substrate drugs. Previous studies indicated that 20(S)-ginsenoside Rh2 [20(S)-Rh2] could synergistically enhance the anticancer effects of conventional chemotherapeutic agents at a nontoxic dose. The aim of present study was to investigate in vitro and in vivo whether 20(S)-Rh2 was a P-gp inhibitor and analyze the possible inhibitory mechanisms and potential herb-drug interactions. Results showed that in vitro, 20(S)-Rh2 significantly enhanced rhodamine 123 retention in cells and decreased the efflux ratio of digoxin, fexofenadine, and etoposide, which were comparable to the effects of the established P-gp inhibitor verapamil. However, the transport of 20(S)-Rh2 suggested that 20(S)-Rh2 was not a P-gp substrate. Furthermore, the inhibitory effect persisted for at least 3 h after removal of 20(S)-Rh2. Unlike P-gp substrates, 20(S)-Rh2 inhibited both basal and verapamil-stimulated P-gp ATPase activities. It also significantly decreased UIC2 binding fluorescence, a marker for conformational change of P-gp. In situ and in vivo experiments showed that 20(S)-Rh2 increased the area under the plasma concentration-time curve and maximum plasma concentration of digoxin, fexofenadine, and etoposide significantly without affecting terminal elimination half-time. Long-term treatment with 20(S)-Rh2 failed to affect intestinal P-gp expression in vitro and in vivo. In conclusion, 20(S)-Rh2 is a potent noncompetitive P-gp inhibitor, which indicates a potential herb-drug interaction when 20(S)-Rh2 is coadministered with P-gp substrate drugs. It could increase the absorption of P-gp substrate drugs without long-term induction of P-gp expression in rats.Keywords
This publication has 36 references indexed in Scilit:
- Intestinal absorption mechanisms of ginsenoside Rh2: stereoselectivity and involvement of ABC transportersXenobiotica, 2010
- Pharmacokinetic characterization of ginsenoside Rh2, an anticancer nutrient from ginseng, in rats and dogsFood and Chemical Toxicology, 2009
- Curcuma drugs and curcumin regulate the expression and function of P-gp in Caco-2 cells in completely opposite waysInternational Journal of Pharmaceutics, 2008
- Rapid Identification of P-glycoprotein Substrates and InhibitorsDrug Metabolism and Disposition, 2006
- Quantitative determination of ginsenoside Rh2 in rat biosamples by liquid chromatography electrospray ionization mass spectrometryAnalytical and Bioanalytical Chemistry, 2006
- Rh2, a compound extracted from ginseng, hypersensitizes multidrug-resistant tumor cells to chemotherapyCanadian Journal of Physiology and Pharmacology, 2004
- Reversal of Daunomycin and Vinblastine Resistance in Multidrug-Resistant P388 Leukemiain vitrothrough Enhanced Cytotoxicity by TriterpenoidsPlanta Medica, 1995
- Inhibition of human ovarian cancer cell proliferation in vitro by ginsenoside Rh2 and adjuvant effects to cisplatin in vivoAnti-Cancer Drugs, 1991
- Chemical Studies on Crude Drug Precession. I. On the Constituents of Ginseng Radix Rubra (1)YAKUGAKU ZASSHI, 1983
- A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye bindingAnalytical Biochemistry, 1976